Opiant Pharmaceuticals (OPNT) Lowered to “Sell” at ValuEngine

ValuEngine lowered shares of Opiant Pharmaceuticals (NASDAQ:OPNT) from a hold rating to a sell rating in a research note published on Friday.

Separately, TheStreet upgraded shares of Opiant Pharmaceuticals from a c+ rating to a b rating in a research report on Monday, October 16th.

Opiant Pharmaceuticals (NASDAQ:OPNT) traded up $1.70 on Friday, reaching $24.95. 62,810 shares of the company’s stock were exchanged, compared to its average volume of 83,505. Opiant Pharmaceuticals has a one year low of $5.00 and a one year high of $51.90. The stock has a market capitalization of $48.08, a PE ratio of 59.40 and a beta of -2.33.

Opiant Pharmaceuticals (NASDAQ:OPNT) last released its quarterly earnings data on Monday, December 4th. The technology company reported ($2.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.19) by ($1.58). Opiant Pharmaceuticals had a net margin of 8.93% and a return on equity of 42.44%. The firm had revenue of $0.02 million during the quarter. analysts predict that Opiant Pharmaceuticals will post 0.17 EPS for the current year.

In other news, major shareholder Geoffrey Wolf sold 2,570 shares of Opiant Pharmaceuticals stock in a transaction dated Friday, December 8th. The shares were sold at an average price of $30.40, for a total value of $78,128.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 63.82% of the stock is owned by company insiders.

ILLEGAL ACTIVITY NOTICE: “Opiant Pharmaceuticals (OPNT) Lowered to “Sell” at ValuEngine” was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this report on another website, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.com-unik.info/2017/12/23/opiant-pharmaceuticals-opnt-lowered-to-sell-at-valuengine.html.

About Opiant Pharmaceuticals

Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).

Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit